Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
  • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
  • A61K8/4966—Triazines or their condensed derivatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
  • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/73—Polysaccharides
  • A61K8/731—Cellulose; Quaternized cellulose derivatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/73—Polysaccharides
  • A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
  • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
  • A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
  • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
  • A61K8/8158—Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/16—Emollients or protectives, e.g. against radiation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
  • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
  • A61K2800/42—Colour properties
  • A61K2800/43—Pigments; Dyes
  • A61K2800/434—Luminescent, Fluorescent; Optical brighteners; Photosensitizers

Definitions

• the present invention relates to the use of a polymeric carrier material treated with a fluore ⁇ scent whitening agent, for lightening human skin and for protecting human skin against UV radiation.
• Melanin is a dark pigment that is found in the hair, the eyes and, especially, the skin, and that is formed in the so-called melanocytes by the conversion of the amino acid tyrosine in the presence of the enzyme tyrosinase.
• the number of melanocytes varies widely according to individual skin type.
• depigmentation agents or bleaching agents e.g. hydroquinone, hydroquinone derivatives, hydrocortisone and retime acid, benzoyloxyphenol (US-A-3 060 097) or methoxyphenol.
• depigmentation agents or bleaching agents e.g. hydroquinone, hydroquinone derivatives, hydrocortisone and retime acid, benzoyloxyphenol (US-A-3 060 097) or methoxyphenol.
• depigmentation agents or bleaching agents e.g. hydroquinone, hydroquinone derivatives, hydrocortisone and retime acid, benzoyloxyphenol (US-A-3 060 097) or methoxyphenol.
• Such components bring about depigmentation by the oxidation or reduction of melanin, but a disadvantage of those active ingredients is that they may cause undesired skin reactions, or satisfactory formulation thereof into cosmetic preparations is not possible.
• the problem of the present invention is to make available skin-lightening compositions that on the one hand have the effect of lightening the skin and that on the other hand are well tolerated by the skin and can be formulated cosmetically.
• a polymeric carrier material treated with a fluorescent whitening agent meets those requirements.
• such a material protects the human skin from the damaging effect of UV rays.
• the present invention accordingly relates to the use of a polymeric carrier material treated with a fluorescent whitening agent for lightening human skin and for protecting human skin against UV radiation.
• Preferred fluorescent whitening agents that can be used in accordance with the invention correspond to the formula
• Ri is a radical of formula
• R 3 is M; unsubstituted or substituted alkyl or unsubstituted or substituted aryl;
• R 4 is hydrogen; unsubstituted or substituted alkyl or unsubstituted or substituted aryl; or -NR 6 R , wherein R 6 and R 7 are each independently of the other hydrogen; unsubstituted or substituted alkyl or unsubstituted or substituted aryl; or R 6 and R 7 together with the nitrogen atom binding them form a heterocyclic radical, especially a morpholino o ⁇ piperidino radical,
• R 5 is hydrogen, unsubstituted or substituted alkyl or unsubstituted or substituted aryl, or a radical of formula (1a) — (CH 2 )-O-SO 3 -M ; x 2
• R 2 is hydrogen; unsubstituted or substituted alkyl or unsubstituted or substituted aryl; or a
• R 1 and R 2 are each independently of the other -OH, -Cl; -NH , -O-C -C alkyl, -O-aryl, -NH-C C 4 alkyl, -N(C 1 -C 4 alkyl) 2 , -N(C 1 -C 4 alkyl)(hydroxy-C 1 -C 4 alkyl), -N(hydroxy- C -C 4 alkyl) 2 ; -NH-aryl, morpholino; or S-C ⁇ C ⁇ alky aryl); R 8 and R 9 are each independently of the other hydrogen, C C 4 alkyl, phenyl or a radical of
• R is hydrogen, Cl or SO 3 M
• R ⁇ n is -CN, -SO 3 M, -SfC ⁇ alkyl)., or S(aryl) 2 ;
• R 12 is hydrogen, -SO 3 M, -O-CyC ⁇ alkyl, -CN, -Cl, -COO-C C 4 alkyl or CON(C 1 -C 4 alkyl) 2 ;
• R 13 is hydrogen; -C 1-C 4 alkyl, -Cl or -SO ,M;
• R and R 15 are each independently of the other hydrogen, C ⁇ C ⁇ aikyl, -SO3M, -Cl or
• R is hydrogen or C ⁇ C ⁇ alkyl
• R 17 is hydrogen, Chalky!, -CN, -Cl, -COO-C C 4 alkyl, -CON(C C 4 alkyl) 2 , aryl or -O-aryl;
• M is hydrogen, Na, K, Ca, Mg, ammonium, mono-, di-, tri- or tetra-C 1 -C 4 alkylammonium, mono-, di- or tri-C 1 -C 4 hydroxyalkylammonium, or ammonium di- or tri-substituted by a mixture of C -C 4 alkyl and C 1 -C 4 hydroxyalkyl groups;
• n-j, n 2 and n 3 are each independently of the others 0 or 1 ;
• x 2 is from 1 to 3.
• R 2 , R 3 , R , R 5 , R 6 and R 7 in the meaning of (unsubstituted or) substituted alkyl is C--C 12 alkyl, preferably C C alkyl.
• the alkyl groups may be branched or unbranched and may be unsubstituted or substituted by halogen, e.g. fluorine, chlorine or bromine, by C C alkoxy, e.g. methoxy or ethoxy, by phenyl or carboxyl, by CrC ⁇ alkoxycarbonyl, e.g. acetyl, by mono- or di-C- ⁇ -C 4 alkylamino or by -SO 3 M.
• Re and R 7 in the meaning of (unsubstituted or) substituted aryl is preferably a phenyl or naphthyl group that may be unsubstituted or substituted by C C 4 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, by C C 4 alkoxy, e.g. methoxy. ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy or tert-butoxy, by halogen, e.g.
• the compounds of formula (1 ) are preferably used in neutral form, that is to say M is preferably a cation of an alkali metal, especially sodium, or an amine. ln the compounds of formula (1 ), R-i is preferably a radical of formula — NH— —co— R
• R 3 has the meanings given above and is preferably d-C 4 alkyl, especially methyl or
• R 6 and R 7 have the meanings given above and are preferably hydrogen, C C 4 alkyl, especially methyl or ethyl, a morpholino or piperidino radical, more especially hydrogen, or a radical of formula
• d-C alkyl substituted by -SO 3 M especially methyl or ethyl substituted by -SO 3 M, wherein K has the meanings given above and is preferably sodium;
• R 2 is preferably — N ⁇ ) , -NH 2 , -N(CH 2 CH 2 OH) 2 or -N[CH 2 CH(OH)CH 3 ] 2 .
• the compounds of formula (1 ) can be prepared under known reaction conditions by the reaction of cyanuric chloride with the corresponding aminostilbenesulfonic acids and with an amino compound that is capable of introducing a group R 1 and with a compound that is capable of introducing a group R 2 , Ri and R 2 having the meanings given above.
• the fluorescent whitening agents that can be used with advantage in the present invention are listed by way of example in the following Table 1 :
• polymeric carriers for use in accordance with the invention there come into consideration materials that are suitable for cosmetic or pharmaceutical preparations.
• the polymeric materials may be of natural origin or are obtainable synthetically, e.g. starch, starch derivatives, e.g.
• hydroxypropyl-distarch phosphate polyvinylpyrrolidones, polyvinyl- polypyrrolidones, polyacrylates, acrylates/steareth-20, methacrylate copolymers, acrylate copolymers, acrylate-octylpropenamide copolymer (Dermacryl 79), aery late/vinyl isodeca- noate cross polymer, C ⁇ opolycarbamyl-polyglycol esters; CrCi ⁇ polycarbamyl-polyglycol esters, acrylate/hydroxy ester acrylate copolymer, acrylate-octylacrylamide; polyacrylamide; polyamides, polyvinylcaprolactam, polyvinyl alcohols, polyolefin dispersions, polyesters, sodium polystyrenesulfonates, latex particles (of all kinds of polymers and copolymers), chito- san and derivatives, xanthans,
• the polymeric material preferably used is cellulose.
• a polymeric carrier material treated with a fluorescent whitening agent the above-mentioned fluorescent whitening agents can be applied to an appropriate carrier. This can be carried out by mixing the carrier materials with the appropriate fluorescent whitening agent in a suitable solvent.
• a solvent in which the fluorescent whitening agent is soluble but the polymeric carrier material is insoluble is used, the dissolved fluorescent whitening agent can be applied directly to the polymeric carrier material. The solvent can be removed from the resulting treated polymeric carrier material by suitable physical separating methods.
• the entire whitening agent/polymeric carrier material/solvent mixture can be incorporated into an appropriate cosmetic or pharmaceutical formulation. It is, however, also possible to remove the solvent from the mixture by suitable methods before the mixture is used further.
• the polymeric carrier materials treated with a fluorescent whitening agent can also be prepared by chemical reaction of the polymeric carrier material with the appropriate fluorescent whitening agent.
• the polymeric carrier materials treated with a fluorescent whitening agent so obtained are suitable for lightening human skin. They simultaneously offer effective protection against UV radiation. A further advantage of such materials is that the actual active substance, that is the fluorescent whitening agent, does not come into direct contact with the skin.
• the treated polymeric carrier materials can be incorporated into appropriate formulations.
• the invention accordingly relates also to a cosmetic formulation that comprises a polymeric carrier material treated with a fluorescent whitening agent, as well as cosmetically tolerable carriers or adjuvants.
• the cosmetic formulation may, in addition to containing the polymeric carrier material treated with a fluorescent whitening agent, also contain one or more further UV-protective substances from the following classes of substance: 1. p-aminobenzoic acid derivatives, e.g. 4-dimethylaminobenzoic acid 2-ethylhexyl ester;
• salicylic acid derivatives e.g. salicylic acid 2-ethylhexyl ester
• benzophenone derivatives e.g. 2-hydroxy-4-methoxybenzophenone and the 5-sulfon ⁇ c acid derivative thereof;
• dibenzoylmethane derivatives e.g. 1-(4-tert-butylphenyl)-3-(4-methoxyphenyl)propane- 1 ,3-dione;
• diphenyl acrylates e.g. 2-ethylhexyl-2-cyano-3,3-diphenyl acrylate and 3-(benzofuranyl)- 2-cyanoacrylate;
• benzofuran derivatives especially 2-(p-aminophenyl)benzofuran derivatives, described in EP-A-582 189, US-A-5 338 539, US-A-5 518 713 and EP-A-613 893;
• polymeric UV absorbers e.g. the benzylidene malonate derivatives described in EP-A-709 080;
• cinnamic acid derivatives e.g. the 4-methoxycinnamic acid 2-ethylhexyl ester and isoamyl ester disclosed in US-A-5 601 811 and WO 97/00851 ;
• camphor derivatives e.g. 3-(4'-methyl)benzylidene-bornan-2-one, 3-benzylidene- boman-2-one, N-[2(and 4)-2-oxybom-3-ylidene-methyl)-benzyl]acrylamide polymer, 3- (4'-trimethylammonium)-benzylidene-bornan-2-one methyl sulfate, 3,3'-(1 ,4- phenylenedimethine-bis(7,7-dimethyl-2-oxo-bicyclo[2.2.1]heptane-1 -methanesulfon ⁇ c acid) and salts, 3-(4'-sulfo)benzylidene-bornan-2-one and salts;
• trianilino-s-triazine derivatives e.g. 2,4,6-trianilino-(p-carbo-2'-ethyl-1 '-oxy)-1 ,3,5-tr ⁇ az ⁇ ne and the UV absorbers disclosed in US-A-5 332 568, EP-A-517 104, EP-A-507 691 , WO 93/17002 and EP-A-570 838;
• R T and R 2 are each independently of the other C 3 -C ⁇ 8 alkyl; C 2 -C 18 alkenyl; or a radical of formula -CH 2 -CH(-OH)-CH 2 -0-T 1 ; or
• R and R 2 are a radical of formula (31a)
• R 12 is a direct bond, a straight-chain or branched d-C 4 alkylene radical or a radical of formula -C m-tH- 2 1 or -C m m tH 2—m. O- ;
• R 13 , R 14 and R 15 are each independently of the others d-dsalkyl; d-C 18 alkoxy or a
• R 16 is d-C 5 alkyl; mi and m 3 are each independently of the other from 1 to 4;
• Pi is 0 or a number from 1 to 5;
• A- is a radical of formula
• R 3 is hydrogen; C C 10 alkyl; -(CH 2 CHR 5 -0) -R. ; or a radical of formula n 1
• R 4 is hydrogen; M; d-C 5 alkyl; or a radical of formula -(CH 2 ) m -0-T 1
• R 5 is hydrogen; or methyl
• T-i is hydrogen; or C ⁇ -C 8 alkyl
• QT is d-C 18 alkyl
• micronised organic UV absorbers especially compounds of formula
• T-i is hydrogen; or d-C 12 alkyl; more especially benzotriazole compounds of formula (32a) wherein
• T T has the meanings given for formula (32) and is preferably methyl, tert-butyl or isooctyl.
• UV absorbers described in “Sunscreens”, Eds. N.J. Lowe, N.A.Shaath, Marcel Dekker, Inc. , New York and Basle or in Cosmetics & Toiletries (107), 50ff (1992) can be used as additional UV-protective substances in the formulation according to the invention
• the cosmetic or pharmaceutical formulation according to the invention can furthermore also be used together with known antioxidants, e.g. vitamin E, carotinoids or flavonoids.
• the cosmetic formulation according to the invention contains from 0.1 to 15 % by weight, preferably from 0.5 to 10 % by weight, based on the total weight of the composition, of a polymeric carrier material treated with a fluorescent whitening agent, as well as a cosmetically tolerable adjuvant.
• the cosmetic or pharmaceutical formulation can be prepared by physically mixing the treated polymeric carrier material with the adjuvant using customary methods, e.g. by simply stirring together the individual components.
• the cosmetic formulation according to the invention may be formulated as a water-in-oil or oil-in-water emulsion, as an oil-in-alcohol lotion, as a vesicular dispersion of an ionic or non- ionic amphiphilic lipid, as a gel, cream or lotion, a solid stick, powder, make-up, foam, paste suspension or stick, or as an aerosol formulation.
• the cosmetically/pharmaceutically tolerable adjuvant contains preferably from 5 to 50 % of an oily phase, from 5 to 20 % of an emulsifier and from 30 to 90 % water.
• the oily phase may comprise any oil suitable for cosmetic/pharmaceutical formulations, e.g. one or more hydrocarbon oils, a wax, a natural oil, a silicone oil, a fatty acid ester or a fatty alcohol.
• Preferred mono- or poly-ols are ethanol, iso- propanol, propylene glycol, hexylene glycol, glyceroi and sorbitol.
• any conventionally used emulsifier can be used for the cosmetic or pharmaceutical formulation according to the invention, e.g. one or more ethoxylated esters of natural derivatives, e.g. polyethoxylated esters of hydrogenated castor oil, or a silicone oil emulsifier, e.g. silico- ne polyol; a fatty acid soap which may or may not be ethoxylated; an ethoxylated fatty alcohol; a sorbitan ester which may or may not be ethoxylated; an ethoxylated fatty acid; or an ethoxylated glyceride.
• one or more ethoxylated esters of natural derivatives e.g. polyethoxylated esters of hydrogenated castor oil, or a silicone oil emulsifier, e.g. silico- ne polyol
• a fatty acid soap which may or may not be ethoxylated
• the cosmetic or pharmaceutical formulation may also contain further components, e.g. emollients, emulsion stabilisers, skin humectants, thickeners, e.g. xanthan, moisture- retaining agents, e.g. glycerol, preservatives, perfumes and colourants.
• emollients e.g. emollients, emulsion stabilisers, skin humectants, thickeners, e.g. xanthan, moisture- retaining agents, e.g. glycerol, preservatives, perfumes and colourants.
• the carrier materials treated with a fluorescent whitening agent that can be used in accordance with the invention are also suitable for improving the appearance of cosmetic or pharmaceutical formulations.
• the intrinsic colour especially of cosmetic formulations is an undesirable beige, or is even yellowish, as a result of the intrinsic colour of the components.
• the use of a polymeric carrier material treated with a fluorescent whitening agent according to the invention allows the degree of whiteness of such formulations to be increased.
• the UV-absorbing properties of those carrier materials provides such products and their components with effective protection against the damaging effect of UV radiation.
• the invention relates also to the use of the carrier materials treated with a fluorescent whitening agent for improving the degree of whiteness of cosmetic or pharmaceutical formulations.
• Example 1 Fluorescent whitening agent immobilised on a starch derivative 0.5 g of the fluorescent whitening agent of formula
• Example 2 Fluorescent whitening agent immobilised on an acrylate/tert-octylpropenamide copolymer
• Example 3 Fluorescent whitening agent immobilised on starch 0.3 g of the fluorescent whitening agent of formula
• phase (A) With stirring at 80°C, phase (A) is introduced into phase B and the batch is homogenised.
• Phase (C) (slurry) is added thereto at 40°C while stirring well and the batch is allowed to cool, with stirring.
• Phases (A) and (B) are separately heated to 80°C and combined without stirring. After the addition of (C), the batch is intensively homogenised. With gentle stirring, the batch is cooled to room temperature. The compound of formula (104) (D), adjusted to pH 5.5 using citric acid (20 % solution), is added in portions with careful stirring. For the purpose of thorough mixing, the batch is then stirred for a further 15 min.. Finally, the desired final pH value is set using (E).
• Phases (A) and (B) are separately heated to 75°C. With stirring, phase (B) is slowly added to phase (A) and the batch is slowly cooled down to 40°C. After brief intensive homogenisation, the batch is allowed to cool to room temperature with stirring.
• Phase (B) is heated to 80°C and maintained at that temperature for 20 min. with stirring.
• Phase (A) likewise heated to 80°C, is added thereto with stirring and the batch is subsequently stirred for 10 min., cooled to 40°C and intensively homogenised. The batch is then allowed to cool to room temperature.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Birds (AREA)
• Epidemiology (AREA)
• Dermatology (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Toxicology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Cosmetics (AREA)
• Detergent Compositions (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Prostheses (AREA)
• Liquid Crystal Substances (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=8243184

Family Applications (1)

Country Status (8)

Cited By (22)

Families Citing this family (8)

Citations (2)

Family Cites Families (2)

• 2000
  • 2000-12-07 ES ES00987366T patent/ES2295075T3/es not_active Expired - Lifetime
  • 2000-12-07 DE DE60037135T patent/DE60037135T2/de not_active Expired - Fee Related
  • 2000-12-07 US US10/149,396 patent/US6818205B2/en not_active Expired - Fee Related
  • 2000-12-07 AT AT00987366T patent/ATE378091T1/de not_active IP Right Cessation
  • 2000-12-07 WO PCT/EP2000/012342 patent/WO2001043714A1/en not_active Ceased
  • 2000-12-07 JP JP2001544654A patent/JP2003516954A/ja not_active Withdrawn
  • 2000-12-07 EP EP00987366A patent/EP1237536B1/en not_active Expired - Lifetime
  • 2000-12-07 AU AU23635/01A patent/AU2363501A/en not_active Abandoned

Patent Citations (2)

Also Published As

Similar Documents

Legal Events